Elyxium Wealth LLC Makes New Investment in Gilead Sciences, Inc. (NASDAQ:GILD)

Elyxium Wealth LLC acquired a new position in shares of Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) during the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor acquired 2,917 shares of the biopharmaceutical company's stock, valued at approximately $327,000.

Other institutional investors and hedge funds also recently made changes to their positions in the company. OneAscent Family Office LLC lifted its position in Gilead Sciences by 75.7% in the 1st quarter. OneAscent Family Office LLC now owns 8,984 shares of the biopharmaceutical company's stock valued at $1,006,000 after acquiring an additional 3,871 shares in the last quarter. Berkeley Capital Partners LLC bought a new position in Gilead Sciences in the 1st quarter valued at about $211,000. AustralianSuper Pty Ltd lifted its position in Gilead Sciences by 168.6% in the 1st quarter. AustralianSuper Pty Ltd now owns 3,057,707 shares of the biopharmaceutical company's stock valued at $342,616,000 after acquiring an additional 1,919,438 shares in the last quarter. Kestra Private Wealth Services LLC lifted its position in Gilead Sciences by 0.8% in the 1st quarter. Kestra Private Wealth Services LLC now owns 29,596 shares of the biopharmaceutical company's stock valued at $3,316,000 after acquiring an additional 228 shares in the last quarter. Finally, Fountainhead AM LLC bought a new position in Gilead Sciences in the 1st quarter valued at about $493,000. Institutional investors own 83.67% of the company's stock.

Gilead Sciences Stock Performance

Gilead Sciences stock traded down $0.58 during mid-day trading on Friday, reaching $108.22. The company's stock had a trading volume of 6,627,889 shares, compared to its average volume of 7,673,118. The firm's fifty day moving average price is $108.81 and its two-hundred day moving average price is $105.26. The company has a debt-to-equity ratio of 1.16, a quick ratio of 1.23 and a current ratio of 1.37. Gilead Sciences, Inc. has a 12-month low of $70.78 and a 12-month high of $119.96. The company has a market capitalization of $134.62 billion, a P/E ratio of 22.78, a PEG ratio of 0.70 and a beta of 0.29.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last announced its quarterly earnings results on Thursday, April 24th. The biopharmaceutical company reported $1.81 EPS for the quarter, beating the consensus estimate of $1.77 by $0.04. Gilead Sciences had a net margin of 20.76% and a return on equity of 51.93%. The firm had revenue of $6.67 billion during the quarter, compared to the consensus estimate of $6.77 billion. During the same period last year, the firm earned ($1.32) EPS. The business's quarterly revenue was down .3% compared to the same quarter last year. Sell-side analysts predict that Gilead Sciences, Inc. will post 7.95 EPS for the current fiscal year.

Gilead Sciences Announces Dividend

The company also recently declared a quarterly dividend, which was paid on Friday, June 27th. Shareholders of record on Friday, June 13th were issued a $0.79 dividend. This represents a $3.16 annualized dividend and a yield of 2.92%. The ex-dividend date of this dividend was Friday, June 13th. Gilead Sciences's payout ratio is 66.53%.

Wall Street Analysts Forecast Growth

Several equities analysts recently weighed in on GILD shares. Cantor Fitzgerald started coverage on shares of Gilead Sciences in a research report on Tuesday, April 22nd. They issued an "overweight" rating and a $125.00 price target on the stock. JPMorgan Chase & Co. lifted their target price on shares of Gilead Sciences from $120.00 to $130.00 and gave the stock an "overweight" rating in a research report on Thursday, March 27th. Oppenheimer dropped their target price on shares of Gilead Sciences from $132.00 to $125.00 and set an "outperform" rating on the stock in a research report on Friday, April 25th. Needham & Company LLC reissued a "hold" rating on shares of Gilead Sciences in a research report on Wednesday, May 21st. Finally, Morgan Stanley lifted their target price on shares of Gilead Sciences from $130.00 to $135.00 and gave the stock an "overweight" rating in a research report on Friday, April 25th. Nine equities research analysts have rated the stock with a hold rating, fourteen have given a buy rating and three have assigned a strong buy rating to the company's stock. Based on data from MarketBeat, Gilead Sciences currently has an average rating of "Moderate Buy" and a consensus price target of $111.38.

Insider Activity

In other news, CEO Daniel Patrick O'day sold 10,000 shares of Gilead Sciences stock in a transaction on Monday, June 30th. The shares were sold at an average price of $110.45, for a total transaction of $1,104,500.00. Following the completion of the sale, the chief executive officer directly owned 615,725 shares of the company's stock, valued at approximately $68,006,826.25. The trade was a 1.60% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, Director Jeffrey Bluestone sold 5,000 shares of Gilead Sciences stock in a transaction on Monday, July 14th. The stock was sold at an average price of $109.74, for a total transaction of $548,700.00. Following the sale, the director directly owned 8,920 shares of the company's stock, valued at $978,880.80. This represents a 35.92% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 72,000 shares of company stock valued at $7,844,775 in the last quarter. 0.27% of the stock is currently owned by company insiders.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.